Healthcare Industry News: PARP inhibitor
News Release - March 9, 2006
Inotek Pharmaceuticals hires Emma Reeve as Chief Financial OfficerBEVERLY, Mass.--(HSMN NewsFeed)--March 9, 2006--Inotek Pharmaceuticals Corporation announced today that it has hired Emma Reeve as Vice President & Chief Financial Officer. For nearly 20 years, Ms. Reeve has led finance and operations functions in small and large, public and private companies. In 1994, Ms. Reeve joined Bristol-Myers Squibb, where she held various financial management positions at both the divisional and corporate level including her final position as Assistant Controller - Financial Analysis. In 2002, she left BMS to join an emerging oncology biotechnology firm, Aton Pharma, Inc., as Vice President & Chief Financial Officer. Aside from her responsibilities in finance and operations at Aton, she was also a lead member of the team that sold the company to Merck & Co., Inc. in March of 2004. Following the acquisition of Aton, Ms. Reeve joined the Merck Research Laboratories' Boston team as site head of Research Operations. In this role, Ms. Reeve and her team supported all aspects of the growth of the site from initial occupancy to the delivery of pre-clinical candidates in oncology.
About Inotek Pharmaceuticals
Inotek Pharmaceuticals Corporation (www.inotekcorp.com) is a private, high-growth, development-stage pharmaceutical company. Inotek has two products in clinical development and five other products in pre-clinical development targeting oncology, cardiovascular, and inflammatory diseases. The Company is pursuing indications in hospital cardiovascular markets as well as specialty care markets including oncology, dermatology and gastroenterology. All of Inotek's technologies were discovered and developed by Inotek researchers. The Company currently has approximately 120 employees, based in its headquarters and main laboratories in Beverly, Massachusetts and its clinical operations and GMP manufacturing facilities in Israel.
The Company's lead clinical program is focused on the development of potent oral and i.v. inhibitors of the nuclear enzyme poly (ADP-ribose) polymerase or PARP. Inotek's lead PARP inhibitor has entered two Phase 2a trials in acute cardiovascular indications as well as several Phase 1b trials in oncology. Inotek's other clinical stage product, an oral anti-inflammatory compound, entered clinical trials earlier in 2006 and is being developed as treatment for inflammatory bowel disease and other inflammatory conditions.
Source: Inotek Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.